Migraine Market Analysis 2019: Key Findings, Regional Analysis, Top Key Players Profiles, Size, Statistics, Industry Growth Rate and Forecasts Till 2022
Business Planning Consulting Services
Updated on Nov 20, 2019
View more like this | Visit United States Minor Outlying Islands, UN | Contact Market Research Future
Migraine Market Analysis
Migraine is the third most widespread and sixth most considerable illness in the world, which has affected near about 37 million people in the U.S. It is a kind of headache with the symptoms of nausea, vomiting, or sensitivity to light and sound. The disease has a main and a key symptom of throbbing pain on one side of the head. Increasing prevalence of the migraine and surge in adoption of novel therapeutics targeting large populations situated globally are driving growth of the global migraine market.
Launch of the calcitonin gene-related peptide (CGRP)-based drugs and therapies by considering it as a novel drug are fueling growth of the global migraine market. Additionally, the key players are focusing on developing efficient drugs, and therapeutics for effective treatment of migraine are driving growth of the market. The other factor benefiting market growth is shifting preference from standard therapeutics treating symptoms to novel and disease-specific therapies.
The rise in drug development activities and investment in R&Ds to trace the unmet need for advanced migraine treatment is leading to an increasing number of drugs in the clinical trials. These drugs are modified based on guidelines set by the government and for the production of drugs. These drugs follow the superior clinical efficacy and most efficacy than the other drugs market by competitors. This is estimated to augment growth of the global migraine market.
Further, the current research focusing on the development of CGRP-based drugs, as well as the introduction of monoclonal antibodies, are driving growth of the global migraine market. The surge in approval of drugs by the U.S. Food and Drugs Administration (FDA) as a preventive measure is benefiting growth of the global migraine market. The factors, as mentioned above, are estimated to offer several opportunities for growth of the global migraine market in the coming future.
Avail Free Sample Copy at https://www.marketresearchfuture.com/sample_request/2381
Migraine Market Competitive Analysis:
Some of the major companies in the global migraine market include Allergan, Abbott Laboratories, Inc., Impax Laboratories, Eisai Inc., Pfizer, Inc., Eli Lilly and Company, Johnson & Johnson, Kowa Pharmaceuticals America, Klaria, Luitpold Pharmaceuticals, Merck, Meda, OptiNose, GlaxoSmithKline plc, and AstraZeneca plc.
Migraine Market Segmentation:
The migraine market is segmented on type, treatment type, drug class, and region.
On the basis of type, the migraine market report is segmented into chronic and pisodic. On the basis of treatment types, the market report is segmented into preventive and abortive. On the basis of drugs, the migraine market is segmented into triptans, ergots, and others.
Migraine Market Regional Analysis:
Regionally, the migraine market is segmented into the Americas, Asia-Pacific, Europe, and Middle East & Africa. Of these, North America is estimated to remain dominant in the global migraine market in the coming period owing to the large patient pool and increased investment in developing newer migraine drugs. Additionally, the market in the Asia Pacific is expected to expand by exhibiting the most lucrative CAGR owing to the high investment in drug development and growing awareness about the availability of efficient drugs for migraine diseases.
Migraine Market Industry News:
October 2019, Alder BioPharmaceuticals, Inc. announced the dosing of the first patient in Phase 1 clinical study to evaluate ALD1910 as a preventive treatment for migraine. Also, the company will be acquired by Danish drugmaker Lundbeck. If the drug receives approval, it will be the first drug approved by the company after acquisition; thus, another key player will be introduced in the market.
In October 2019, Eli Lilly Canada Inc announced the availability of Emgality in Canada. This dug will be a preventive measure for the migraine in adults with the highest intensity.
October 2019, FDA cleared the Nerivio Migra, a wearable, the BIPRI 8-Motor Headband device by the company, Theranica Bio-Electronics Ltd. The device offers vibration therapy to users to relief to the migraine. Additionally, these wearables are the acute treatment of migraine with or without aura in adults.